Prosecution Insights
Last updated: November 04, 2026

Beijing Avistone Biotechnology Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Beijing Avistone Biotechnology Co. Ltd. currently faces 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is being processed in 1 distinct art unit by 1 distinct examiner. The busiest examiner is HEITMEIER, KENDALL NICOLE, who is responsible for 1 pending action. This represents the full extent of the company's current pending office action activity. For a practitioner, this singular focus allows for a highly targeted prosecution strategy.

The involvement of 1 distinct art unit suggests that the company's current biotechnology innovation falls into a specific technical category. Because the prosecution is limited to 1 distinct examiner, the outcome depends entirely on the interactions with HEITMEIER, KENDALL NICOLE. There is no need to manage multiple examiner styles or varying art unit standards. This 1 pending office action can be addressed with a clear understanding of the assigned examiner's specific requirements. The data shows a streamlined prosecution environment where the company's immediate pharmaceutical patent goals are tied to a single examination process, with no other active matters currently pending.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
1
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
HEITMEIER, KENDALL NICOLE 1 63.6% +42.9%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18725596 HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF HEITMEIER, KENDALL NICOLE —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18725596 HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF HEITMEIER, KENDALL NICOLE —

Top Art Units

Art UnitApps
1621 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18725596 HETEROAROMATIC NITROGEN-OXIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF HEITMEIER, KENDALL NICOLE 1621 §103§112 Non-Final OA — Pending Jun 28, 2024

Managing Beijing Avistone Biotechnology Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Beijing Avistone Biotechnology Co. Ltd. have?

Beijing Avistone Biotechnology Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Beijing Avistone Biotechnology Co. Ltd. applications?

Kendall Nicole Heitmeier has the most, with 1 of Beijing Avistone Biotechnology Co. Ltd.'s pending office actions.

What technology area are Beijing Avistone Biotechnology Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month